Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate to suppress immunogenicity to anti-TNF therapy in IBD patients with loss of response
2018-003594-95Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite primary endpoint: suppression of immunogenicity and recapture of clinical remission. Started Apr 2019; status: active.
02
Drugs
methotrexate
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2018-003594-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003594-95.